Skip to main content
. Author manuscript; available in PMC: 2021 Feb 3.
Published in final edited form as: Neurobiol Dis. 2020 Dec 19;149:105225. doi: 10.1016/j.nbd.2020.105225

Fig. 2. Dataset Selection Workflow.

Fig. 2.

Description of the systematic review of human transcriptomics from AD, LBD, and ALS-FTD patients in the Gene Expression Omnibus (GEO) and ArrayExpress databases according to PRISMA guidelines. After applying pre-specified inclusion and exclusion criteria, our systematic review yielded 1677 control and 1563 disease samples from 26 AD, 21 LBD, and 13 ALS-FTD datasets.